Clinical Trials · NCT07794579

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Name: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Orforglipron

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Eli Lilly and Company
Enrollment: 2,001
Start date: Aug 2026
Locations: 180 sites, 12 countries
Primary endpoint: Time to Onset of Obesity Related Complications or Class 1 Obesity

View Orforglipron compound reference